Home > Inhibitors & Agonists > Tyrosine Kinase > FGFR
Cat. No. Product name CAS No.
DC11931 Alofanib Featured

Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM

DC1075 AZD4547 Featured

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively.

DC5194 NVP-BGJ398(Infigratinib) Featured

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

DC10092 BLU554(Fisogatinib) Featured

BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.

DC8280 BLU-9931 Featured

BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).

DC8418 CH5183284 (Debio-1347) Featured

CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

DC10559 Derazantinib (ARQ 087) Featured

Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.

DC4157 Dovitinib (TKI258, CHIR258) Featured

Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

DC10313 Dovitinib lactate

Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM.

DC11387 Erdafitinib Featured

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively.

DC10128 FGF401( Roblitinib) Featured

FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

DC9933 FGFR4-IN-1

FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.

DC8330 FIIN-2 Featured

FIIN-2 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor.

DC9642 FIIN-3 Featured

FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor.

DC10033 H3B-6527 Featured

H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

DC7019 LY-2874455 Featured

LY2874455 is a novel and potent FGF/FGFR inhibitor.

DC9945 NSC-12

NSC12 is a PTX3-derived anti-FGF small molecule, inhibits FGF-dependent tumor growth, angiogenesis, and metastases,acts as a small-molecule FGF trap in cancer therapy.

DC10068 PD166866 Featured

PD-166866 is a selective inhibitor of the FGF-1 receptor tyrosine kinase (FGFR1) with IC50 = 55 nM, and no effect on c-Src, PDGFR-b, EGFR or insulin receptor tyrosine kinases or MEK, PKC, and CDK4.

DC2054 PD-173074 Featured

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM.

DC10641 PRN1371 Featured

PRN1371 is an irreversible covalent FGFR1-4 kinase inhibitor, with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, 2, 3, 4 and CSF1R, respectively.

DC7508 SU 5402 Featured

SU5402(SU-5402; SU5402) is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).

DC10271 SUN11602 Featured

SUN11602 is a novel aniline compound, which mimics the neuroprotective mechanisms of basic fibroblast growth factor.

Page 1 / Total 2 FirstPrevNextLastGoto